Pelthos Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Pelthos Therapeutics (PTHS).

Price Target Range — 6 Quarters

Analyst Consensus — 6 Analysts

6Buy

Consensus RatingBuy# Analysts6Avg. Consensus PT$53Upside to Avg. PT+160.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 12, 2026	Lake Street	Thomas Flaten	PT Cut	Buy	$50→$40
Aug 14, 2026	Oppenheimer	Jeff Jones	PT Cut	Outperform	$66→$64
May 15, 2026	Oppenheimer	Jeff Jones	PT Raise	Outperform	$62→$66
Apr 1, 2026	Cantor Fitzgerald	Olivia Brayer Saunders	Initiate	Overweight	$50
Mar 20, 2026	Oppenheimer	Jeff Jones	PT Raise	Outperform	$60→$62
Mar 19, 2026	HC Wainwright & Co.	Brandon Folkes	Maintained	Buy	$60
Feb 27, 2026	Piper Sandler	David Amsellem	Initiate	Overweight	$48
Feb 26, 2026	Roth Capital	Jonathan Aschoff	PT Cut	Buy	$57→$55
Jan 26, 2026	Oppenheimer	Jeff Jones	PT Raise	Outperform	$57→$60
Dec 3, 2025	Lake Street	Thomas Flaten	Initiate	Buy	$50
Dec 3, 2025	HC Wainwright & Co.	Brandon Folkes	Initiate	Buy	$60
Nov 25, 2025	Roth Capital	Jonathan Aschoff	Initiate	Buy	$57
Nov 14, 2025	Oppenheimer	Jeff Jones	PT Raise	Outperform	$50→$57
Sep 2, 2025	Oppenheimer	Jeff Jones	Initiate	Outperform	$50

Analyst Ratings News

PRO
Lake Street Maintains Buy on Pelthos Therapeutics, Lowers Price Target to $40

Lake Street analyst Thomas Flaten maintains Pelthos Therapeutics (AMEX:PTHS) with a Buy and lowers the price target from $50 to $40.

Benzinga Newsdesk

PRO
Oppenheimer Maintains Outperform on Pelthos Therapeutics, Lowers Price Target to $64

Oppenheimer analyst Jeff Jones maintains Pelthos Therapeutics (AMEX:PTHS) with a Outperform and lowers the price target from $66 to $64.

Benzinga Newsdesk

PRO
Oppenheimer Maintains Outperform on Pelthos Therapeutics, Raises Price Target to $66

Oppenheimer analyst Jeff Jones maintains Pelthos Therapeutics (AMEX:PTHS) with a Outperform and raises the price target from $62 to $66.

Benzinga Newsdesk

PRO
Oppenheimer Maintains Outperform on Pelthos Therapeutics, Raises Price Target to $62

Oppenheimer analyst Jeff Jones maintains Pelthos Therapeutics (AMEX:PTHS) with a Outperform and raises the price target from $60 to $62.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Pelthos Therapeutics, Maintains $60 Price Target

HC Wainwright & Co. analyst Brandon Folkes reiterates Pelthos Therapeutics (AMEX:PTHS) with a Buy and maintains $60 price target.

Benzinga Newsdesk

This Jazz Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday

Top analysts changed outlook on top names. Check analyst ratings page for upgrades, downgrades, initiations. See what they think of JAZZ stock.

Avi Kapoor

Pelthos Therapeutics Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Pelthos Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Lake Street Maintains Buy on Pelthos Therapeutics, Lowers Price Target to $40

PRO
Oppenheimer Maintains Outperform on Pelthos Therapeutics, Lowers Price Target to $64

PRO
Oppenheimer Maintains Outperform on Pelthos Therapeutics, Raises Price Target to $66

PRO
Oppenheimer Maintains Outperform on Pelthos Therapeutics, Raises Price Target to $62

PRO
HC Wainwright & Co. Reiterates Buy on Pelthos Therapeutics, Maintains $60 Price Target

This Jazz Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday

People Also Watch

People Also Watch

Pelthos Therapeutics Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Pelthos Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROLake Street Maintains Buy on Pelthos Therapeutics, Lowers Price Target to $40

PROOppenheimer Maintains Outperform on Pelthos Therapeutics, Lowers Price Target to $64

PROOppenheimer Maintains Outperform on Pelthos Therapeutics, Raises Price Target to $66

PROOppenheimer Maintains Outperform on Pelthos Therapeutics, Raises Price Target to $62

PROHC Wainwright & Co. Reiterates Buy on Pelthos Therapeutics, Maintains $60 Price Target

This Jazz Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday

People Also Watch

People Also Watch

PRO
Lake Street Maintains Buy on Pelthos Therapeutics, Lowers Price Target to $40

PRO
Oppenheimer Maintains Outperform on Pelthos Therapeutics, Lowers Price Target to $64

PRO
Oppenheimer Maintains Outperform on Pelthos Therapeutics, Raises Price Target to $66

PRO
Oppenheimer Maintains Outperform on Pelthos Therapeutics, Raises Price Target to $62

PRO
HC Wainwright & Co. Reiterates Buy on Pelthos Therapeutics, Maintains $60 Price Target